Is Zika congenital syndrome, which affected thousands of babies born in Brazil during epidemics, associated with an increased host genetic susceptibility? And could Zika be a strong oncolytic agent against aggressive brain tumors? Find out in this opinion piece.
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
The first population-level evidence has proved the rotavirus vaccination saves lives in low-income settings.
Vaccination has begun to try and contain the second outbreak of Ebola seen in the Democratic Republic of Congo this year.
New study finds that the oral rotavirus vaccine response could be influenced by changes in the human microbiota.
A study in 20 patients has demonstrated that transplantation followed by antiviral therapy has been successful in patients receiving kidneys from hepatitis C-infected donors.
A perspective piece from authors at NIAID has highlighted tick-borne disease as a growing threat in the US, and has emphasized the need for more research.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
The Joint Committee on Vaccination and Immunisation has stated that a gender-neutral vaccine program would be cost effective in the UK and would protect boys against HPV infection and associated diseases.
In this infographic we take a look at the estimated burden of some key foodborne diseases in terms of both cases and mortality.
